For laboratory research use only - not for human consumption

Compound hub · Retatrutide

How much does retatrutide cost? Is there an approved price?

There is no known price for retatrutide as an approved medicine. The TGA's September 2026 alert reports no approval. Lilly's September 2026 FAQ gives no price (both checked 17 October 2026). So there is no approved pharmacy or PBS price to quote. Research listings and trial results cannot show a future monthly cost. A committee's backing for a different medicine cannot show it either.

Published 2026-10-17Updated 2026-10-17Written by Form Laboratories research team5 min read

A price tag seems simple until you ask what it covers. It could be research material, a maker's public price, or government help with the cost. Each one means something different. Explore the retatrutide evidence index for related records. This page explains the price question for readers of Form Laboratories.

Key facts

Key facts for How much does retatrutide cost? Is there an approved price?
Regulator recordTGA safety alert, 14 September 2026; checked 17 October 2026
Maker's price statementLilly retatrutide FAQ, updated September 2026; no price figure; checked 17 October 2026
Australian subsidy processPBS explanation of PBAC outcomes, updated 16 October 2026; checked 17 October 2026
Tirzepatide exampleMarch 2026 PBAC outcomes, pages 47–48; checked 17 October 2026
Semaglutide exampleNovember 2025 PBAC outcomes, pages 36–38; checked 17 October 2026
TGA, safety alert, 14 September 2026; checked 17 October 2026

Is there an approved retatrutide price in Australia?

The records checked on 17 October 2026 give no price for an approved Australian retatrutide medicine. The TGA is the body that approves medicines in Australia. Its alert of 14 September 2026 says retatrutide has no TGA approval. It also reports no approval from a similar body overseas. That speaks about approval. It does not announce a price. A shop listing cannot give a medicine the approval it lacks. Calling an online figure a pharmacy price would mix up two different things. Start with the approval record for the named product. If an approved product reaches the market, look for a separate price record.

For the wider status question, read Retatrutide in Australia: is it legal, approved or available yet?. That page checks the Australian record. It does not guess a launch cost.

Lilly, What to know about retatrutide, September 2026; checked 17 October 2026

How much will retatrutide cost per month?

Lilly's September 2026 FAQ gives no future monthly cost for retatrutide (checked 17 October 2026). Lilly talks about pricing once trials in people and medicine reviews are done. It gives no amount. A plan to set a price is not a published list price. A list price is the maker's stated price for a named product in a named market. The FAQ cannot show that future price or an Australian pharmacy charge. It also cannot show how much the PBS would pay. A guessed cost would make an unknown look like a fact.

Approval in another country would need its own dated record. What does the public record say about retatrutide in the United States? covers that question. A US status update alone would not show an Australian price.

PBS, PBAC outcomes process explanation; checked 17 October 2026

Who decides whether a medicine has a PBS price?

Approval alone does not set a PBS price. A medicine must go through a separate Australian listing process. The Pharmaceutical Benefits Scheme, or PBS, helps pay for listed medicines. Its advice group, the PBAC, checks the evidence and costs for a proposed listing. PBS guidance explains what happens when this group backs a listing (checked 17 October 2026). The maker and the health department talk about the price. More work covers listing details and checks on quality and supply. The government must also consider it. A maker's public list price and a PBS deal are different things. Neither comes straight from a trial paper.

The same PBS guidance says where listed medicines appear (checked 17 October 2026). They appear in the Schedule of Pharmaceutical Benefits, the list of covered medicines. A committee's backing is one step toward that list. The word Recommended is not a price tag.

Three separate document cards labelled Approval, List price and PBS listing, with a seal, a blank tag and a ledger symbol.
Approval, a maker's list price and a PBS listing are separate records. The PBS guidance lists pricing negotiations and further checks after a PBAC recommendation. Source: PBS, PBAC outcomes process explanation, checked 17 October 2026.
PBAC, March 2026 outcomes, pages 47–48PBAC, November 2025 outcomes, pages 36–38; both checked 17 October 2026

What do the tirzepatide and semaglutide PBAC records show?

These PBAC records back listings for set groups of people. They do not predict a retatrutide price. The March 2026 outcome backs tirzepatide for adults whose type 2 diabetes is not well controlled. The November 2025 outcome backs semaglutide for a set group of adults. That group has known heart or blood vessel disease and obesity. Both entries were checked on 17 October 2026. Each decision covers its own medicine and group. Neither entry gives a date when a PBS listing starts. Read each committee outcome with care. Backing for one listing cannot show the price or listing of another compound.

Read What did the March 2026 PBAC decide on tirzepatide? for a summary tied to that meeting date. The source documents above give both examples in full.

Jastreboff et al., New England Journal of Medicine, 2023TGA, 14 September 2026 safety alert; checked 17 October 2026

Evidence limits

Can research listings or trial papers establish a medicine price?

Research listings and trial papers do not set a price for an approved retatrutide medicine. Jastreboff and colleagues' 2023 paper in the New England Journal of Medicine reports a trial in people. It does not announce a sale price. The study measured changes in body weight and recorded unwanted effects. Those results do not set a launch price. The TGA's September 2026 alert reports a separate finding (checked 17 October 2026). One tested product sold as retatrutide had a different substance inside. One sample cannot show how common wrong labels are. Still, a seller's label alone cannot confirm what is inside.

How are people getting retatrutide? keeps trial records apart from claims made outside trials. The Form Laboratories research catalogue lists research material. Research material is not an approved medicine or a replacement for one. It is not for human or animal use.

Comparison

What each source record shows, checked 17 October 2026. This table compares documents. It does not guess prices or compare personal results.

Comparison: How much does retatrutide cost? Is there an approved price?
RecordWhat it establishesWhat it does not establish
TGA alert, September 2026The TGA reports no retatrutide approval, and none from a similar body overseasAn approved pharmacy price (TGA, 14 September 2026)
Lilly FAQ, September 2026A statement about future pricing after trials and reviewA published retatrutide price figure (Lilly FAQ)
Tirzepatide, March 2026 PBACThe committee backs a listing for adults with type 2 diabetesAn effective listing date in that entry (PBAC, pages 47–48)
Semaglutide, November 2025 PBACThe committee backs a listing for adults with heart or blood vessel disease and obesityA PBS commencement date in that decision (PBAC, pages 36–38)

FAQ

Is a monthly retatrutide cost confirmed?

No. Lilly's September 2026 FAQ confirms no monthly medicine cost (checked 17 October 2026). The maker talks about future pricing but gives no amount. A guessed monthly cost would go beyond that source.

Does TGA approval set a medicine's price?

No. Approval and PBS pricing are separate decisions. PBS guidance explains the steps after a PBAC recommendation (checked 17 October 2026). The committee has then backed a listing. Price talks and other listing work come next.

Does a PBAC recommendation mean a medicine is already listed?

No. PBS guidance names more steps after a recommendation (checked 17 October 2026). The tirzepatide and semaglutide entries give no start dates for listings. They say nothing about later changes.

Can another medicine's price predict retatrutide's price?

The sources here give no such forecast. The two PBAC examples cover different medicines and set uses. Each one shows what the committee decided in that case. Neither shows a future price for retatrutide.

Does a research catalogue establish a pharmacy price?

No. A research catalogue lists a different kind of material. The TGA alert and Lilly's public FAQ were checked 17 October 2026. Neither shows an approved retatrutide price from catalogue listings.

Citations

1 sources
  1. Jastreboff AM, Kaplan LM, Frías JP, et al. New England Journal of Medicine. 2023;389:514–526. Triple-Hormone-Receptor Agonist Retatrutide for Obesity: A Phase 2 Trial.
    doi:10.1056/NEJMoa2301972

Written by

Form Laboratories research team

Perth, Western Australia. We supply research-use-only reference material.

Written in-house
These articles are written and maintained by our own research team, not by a named clinician.
Built from the record
Every figure comes from published literature, listed in full above with a link to the original paper.
No use directions
We describe what the research measured. We give no use directions, preparation steps or advice.

Form Laboratories supplies research-use-only reference material. This article is an educational summary of published third-party literature. It is not medical advice, not a use instruction, and research material is not for human or animal use.

2026 Form Laboratories - Research use only - Perth WAPerth WA 6000 - dispatched Australia-wide via Australia Post or CouriersPlease